Logo image of CVM

CEL-SCI CORP (CVM) Stock Fundamental Analysis

NYSEARCA:CVM - NYSE Arca - US1508376076 - Common Stock - Currency: USD

2.44  -2.07 (-45.9%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CVM. CVM was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of CVM have multiple concerns. CVM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CVM had negative earnings in the past year.
In the past year CVM has reported a negative cash flow from operations.
In the past 5 years CVM always reported negative net income.
In the past 5 years CVM always reported negative operating cash flow.
CVM Yearly Net Income VS EBIT VS OCF VS FCFCVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

CVM has a worse Return On Assets (-125.05%) than 80.75% of its industry peers.
Looking at the Return On Equity, with a value of -340.98%, CVM is doing worse than 74.87% of the companies in the same industry.
Industry RankSector Rank
ROA -125.05%
ROE -340.98%
ROIC N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
CVM Yearly ROA, ROE, ROICCVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVM Yearly Profit, Operating, Gross MarginsCVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, CVM has more shares outstanding
CVM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CVM has been reduced compared to a year ago.
CVM Yearly Shares OutstandingCVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CVM Yearly Total Debt VS Total AssetsCVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CVM has an Altman-Z score of -21.47. This is a bad value and indicates that CVM is not financially healthy and even has some risk of bankruptcy.
CVM's Altman-Z score of -21.47 is on the low side compared to the rest of the industry. CVM is outperformed by 88.06% of its industry peers.
CVM has a Debt/Equity ratio of 0.86. This is a neutral value indicating CVM is somewhat dependend on debt financing.
CVM has a worse Debt to Equity ratio (0.86) than 77.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -21.47
ROIC/WACCN/A
WACCN/A
CVM Yearly LT Debt VS Equity VS FCFCVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.55 indicates that CVM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.55, CVM is doing worse than 93.05% of the companies in the same industry.
CVM has a Quick Ratio of 0.55. This is a bad value and indicates that CVM is not financially healthy enough and could expect problems in meeting its short term obligations.
CVM has a worse Quick ratio (0.39) than 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.39
CVM Yearly Current Assets VS Current LiabilitesCVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

CVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.71%, which is quite impressive.
EPS 1Y (TTM)32.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CVM will show a very strong growth in Earnings Per Share. The EPS will grow by 25.81% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.35%
EPS Next 2Y22.62%
EPS Next 3Y20.44%
EPS Next 5Y25.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVM Yearly Revenue VS EstimatesCVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2024 2026 2027 2028 2029 100M 200M 300M 400M
CVM Yearly EPS VS EstimatesCVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CVM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVM Price Earnings VS Forward Price EarningsCVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVM Per share dataCVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

CVM's earnings are expected to grow with 20.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.62%
EPS Next 3Y20.44%

More info and screens

0

5. Dividend

5.1 Amount

CVM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CEL-SCI CORP

NYSEARCA:CVM (5/22/2025, 3:45:02 PM)

2.44

-2.07 (-45.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-12 2025-08-12
Inst Owners9.14%
Inst Owner Change6.37%
Ins Owners2.34%
Ins Owner Change3.06%
Market Cap205.25M
Analysts80
Price Target7.55 (209.43%)
Short Float %6.68%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.31%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.66
P/tB 26.13
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.1
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.05%
ROE -340.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.93%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.39
Altman-Z -21.47
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)143.31%
Cap/Depr(5y)116.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.22%
EPS Next Y6.35%
EPS Next 2Y22.62%
EPS Next 3Y20.44%
EPS Next 5Y25.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year717.49%
EBIT Next 3Y181.37%
EBIT Next 5YN/A
FCF growth 1Y12.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.08%
OCF growth 3YN/A
OCF growth 5YN/A